Alpha-GPC for sport: evaluating the evidence
Small trials of force production, cognitive tests and growth hormone, including limitations and later findings.
SMTP / IMAP
SMTP / IMAP: an editorial collection on health, supplements, training and pharmacology, with illustrated explanations and original source references.
All articlesSmall trials of force production, cognitive tests and growth hormone, including limitations and later findings.
Clinical study amounts, food effects and course durations, without treating research doses as a universal supplement regimen.
Reversible aromatase inhibition, pharmacokinetics, interactions and the consequences of reduced estrogen in different populations.
From receptor domains and DNA binding to tissue responses, feedback and the limits of simple claims about receptor sensitivity.
Oil-depot absorption, ester cleavage, metabolites and the lack of reliable human data behind frequently quoted half-lives.
Adenosine blockade, alertness, exercise effects and the factors that change how rapidly caffeine leaves the body.
Tremor, palpitations, potassium shifts, arrhythmias and poisoning, with warning signs that require urgent medical assessment.
What clomiphene can and cannot establish about hormonal recovery, dose response, long-term use and anti-doping status.
Older trial findings, a later liver-injury case report, metabolic concerns and the uncertainty of online product composition.
Kidney function, neuromuscular conditions, cardiac conduction and medicine timing all affect the safety of magnesium products.
Energy signaling, intestinal actions, clearance, drug interactions and the limits of equating a medicine with a supplement.
Liver injury, cardiovascular effects, hormonal suppression and product uncertainty, separated by the available level of evidence.
A simple explanation of the proposed MGF model, the role of IGF-1 and why laboratory mechanisms do not prove product benefits.
Aromatization, receptor activity, SHBG and indirect hormonal changes, with a critical look at common combination-use claims.
Why a short ester does not prevent androgenic changes, which effects may persist and how medical treatment differs from sports use.
Hormonal, cardiovascular, liver and fertility assessment, including why symptoms may require testing before drugs have cleared.
Bile composition, transport, cellular protection and cholesterol stones, with a distinction between mechanisms and clinical benefit.
The structure of the Prohibited List, route-dependent rules, specified substances and key distinctions for athletes.